These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28923315)

  • 1. Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
    Liu Y; Cathcart AL; Delaney WE; Kitrinos KM
    J Virol Methods; 2017 Nov; 249():189-193. PubMed ID: 28923315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.
    Martin LA; Stramer SL; Kuhns MC; Schlauder GG
    Transfusion; 2012 Oct; 52(10):2201-8. PubMed ID: 22321072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital.
    Lukhwareni A; Burnett RJ; Selabe SG; Mzileni MO; Mphahlele MJ
    J Med Virol; 2009 Mar; 81(3):406-12. PubMed ID: 19152393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma.
    Allice T; Cerutti F; Pittaluga F; Varetto S; Gabella S; Marzano A; Franchello A; Colucci G; Ghisetti V
    J Clin Microbiol; 2007 Mar; 45(3):828-34. PubMed ID: 17229858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
    Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
    J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa.
    Mphahlele MJ; Lukhwareni A; Burnett RJ; Moropeng LM; Ngobeni JM
    J Clin Virol; 2006 Jan; 35(1):14-20. PubMed ID: 15916918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Cobas Ampliprep/Cobas TaqMan HBV Test versus the Cobas Amplicor HBV monitor for HBV-DNA detection and quantification during antiviral therapy.
    Allice T; Cerutti F; Pittaluga F; Varetto S; Gabella S; Marzano A; Franchello A; Ghisetti V
    New Microbiol; 2008 Jan; 31(1):27-35. PubMed ID: 18437839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
    Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
    PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.